logical diseases can lead to increased erythrocyte zinc protoporphyrin concentrations, significantly increased free protoporphyrin concentrations are assumed to be found exclusively in EPP. Slightly increased levels of free protoporphyrin are observed under conditions of zinc depletion and iron deficiency, sometimes in sideroblastic anemia and other hematological diseases, and in homozygous or compound heterozygous porphyrias such as hepatoerythropoietic porphyria, Doss porphyria (d-aminolevulinate dehydratase-deficiency porphyria) and congenital erythropoietic porphyria (Morbus Guenther). However, clinically relevant concentrations are never attained in these cases.
Since EPP does not present with visible or characteristic skin abnormalities in many cases (10), erythrocyte protoporphyrin measurement is of essential importance for primary diagnosis of EPP in children and adolescents with avoidance behavior towards sun exposure. In the follow-up of EPP patients, erythrocyte protoporphyrin measurement can potentially help (in addition to quantification of fecal protoporphyrin excretion and the isomeric ratio of coproporphyrin in urine) in early recognition of transition of the disease to a fulminate phase, in which worsening cholestasis leads to further accumulation of protoporphyrin in a vicious cycle (4, 5) .
Quantification of free erythrocyte protoporphyrin concentrations still represents an analytical challenge and is performed in only a few specialized laboratories. The first approach to laboratory diagnosis of EPP was the demonstration of fluorescent red cells (''fluorocytes'') in blood films viewed under ultraviolet light (11) . Several chromatographic methods for specific quantification of erythrocyte free protoporphyrin were subsequently described (12, 13) . In such assays, sample preparation with full-recovery analyte extraction is delicate and the chromatographic separation of free from zinc-chelated protoporphyrin is demanding.
Blood-based materials for calibration and quality control of erythrocyte free protoporphyrin quantification are not commercially available at present and no proficiency testing schemes have been implemented. Indeed, there are no data published on agreement between free erythrocyte measurements performed in different laboratories. We therefore decided to organize an inter-laboratory survey study of free erythrocyte protoporphyrin measurement. Data from this survey will be important in achieving harmonization of protoporphyrin measurement in the future.
For this survey, 30 mL of heparinized whole blood was sampled from an EPP patient after informed con-sent and approval by the Institutional Review Board. Erythrocytes were separated from the plasma by centrifugation, and washed with saline. Aliquots of the sample were prepared and lyophilized in lightprotected vials in an industrial setting (Chromsystems, Munich, Germany).
We can now invite interested colleagues to request an aliquot of this sample (michael.vogeser@med.unimuenchen.de) for free erythrocyte protoporphyrin measurement at no cost. The resulting data will be evaluated after anonymization. It is intended to create a research group with the participants of this survey and to submit the data from this pilot investigation for potential publication in Clinical Chemistry and Laboratory Medicine.
